288 related articles for article (PubMed ID: 34025781)
1. The role of PARP inhibitors in
Chi J; Chung SY; Parakrama R; Fayyaz F; Jose J; Saif MW
Therap Adv Gastroenterol; 2021; 14():17562848211014818. PubMed ID: 34025781
[TBL] [Abstract][Full Text] [Related]
2. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
Kasi A; Al-Jumayli M; Park R; Baranda J; Sun W
J Pancreat Cancer; 2020; 6(1):107-115. PubMed ID: 33376937
[No Abstract] [Full Text] [Related]
3. PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session.
Patel R; Fein D; Ramirez CB; Do K; Saif MW
Pancreas (Fairfax); 2019; 3(1):e5-e8. PubMed ID: 32030362
[TBL] [Abstract][Full Text] [Related]
4. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
[TBL] [Abstract][Full Text] [Related]
5. Targeting DNA damage repair pathways in pancreas cancer.
Crowley F; Park W; O'Reilly EM
Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
[TBL] [Abstract][Full Text] [Related]
6. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Sorscher S; Ramkissoon S
Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
[TBL] [Abstract][Full Text] [Related]
7. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
8. Precision Medicine for
Principe DR
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205643
[TBL] [Abstract][Full Text] [Related]
9. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
10. An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
Cortesi L; Rugo HS; Jackisch C
Target Oncol; 2021 May; 16(3):255-282. PubMed ID: 33710534
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Rodler E; Sharma P; Barlow WE; Gralow JR; Puhalla SL; Anders CK; Goldstein L; Tripathy D; Brown-Glaberman UA; Huynh TT; Szyarto CS; Godwin AK; Pathak HB; Swisher EM; Radke MR; Timms KM; Lew DL; Miao J; Pusztai L; Hayes DF; Hortobagyi GN
Lancet Oncol; 2023 Feb; 24(2):162-174. PubMed ID: 36623515
[TBL] [Abstract][Full Text] [Related]
12. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Pujade-Lauraine E; Selle F; Scambia G; Asselain B; Marmé F; Lindemann K; Colombo N; Mądry R; Glasspool R; Vergote I; Korach J; Lheureux S; Dubot C; Oaknin A; Zamagni C; Heitz F; Gladieff L; Rubio-Pérez MJ; Scollo P; Blakeley C; Shaw B; Ray-Coquard I; Redondo A;
Ann Oncol; 2023 Dec; 34(12):1152-1164. PubMed ID: 37797734
[TBL] [Abstract][Full Text] [Related]
13. Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer.
LaRose M; Manji GA; Bates SE
Semin Oncol; 2024; 51(1-2):36-44. PubMed ID: 38171988
[TBL] [Abstract][Full Text] [Related]
14. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
15. Advances in the use of PARP inhibitor therapy for breast cancer.
McCann KE; Hurvitz SA
Drugs Context; 2018; 7():212540. PubMed ID: 30116283
[TBL] [Abstract][Full Text] [Related]
16. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
Faraoni I; Graziani G
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30518089
[TBL] [Abstract][Full Text] [Related]
17. Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells.
Gao Y; Chen MK; Chu YY; Yang L; Yu D; Liu Y; Hung MC
Am J Cancer Res; 2021; 11(1):236-250. PubMed ID: 33520371
[TBL] [Abstract][Full Text] [Related]
18. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
19. Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
Boussios S; Moschetta M; Karihtala P; Samartzis EP; Sheriff M; Pappas-Gogos G; Ozturk MA; Uccello M; Karathanasi A; Tringos M; Rassy E; Pavlidis N
Ann Transl Med; 2020 Dec; 8(24):1706. PubMed ID: 33490218
[TBL] [Abstract][Full Text] [Related]
20. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.
Jiang X; Li W; Li X; Bai H; Zhang Z
Cancer Manag Res; 2019; 11():4371-4390. PubMed ID: 31191001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
